State Street’s Acrivon Therapeutics ACRV Stock Holding History

State Street’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$93.3K	Hold	67,145	–	–	﹤0.01%	4040
2025 Q4	$162K	Hold	67,145	–	–	﹤0.01%	3949
2025 Q3	$122K	Hold	67,145	–	–	﹤0.01%	4015
2025 Q2	$79.9K	Sell	67,145 -165,406	-71%	-$227K	﹤0.01%	4016
2025 Q1	$472K	Sell	232,551 -4,050	-2%	-$21.8K	﹤0.01%	3605
2024 Q4	$1.42M	Buy	236,601 +10,705	+5%	+$77.8K	﹤0.01%	3408
2024 Q3	$1.58M	Buy	225,896 +47,233	+26%	+$372K	﹤0.01%	3396
2024 Q2	$1.04M	Buy	178,663 +45,387	+34%	+$366K	﹤0.01%	3469
2024 Q1	$953K	Hold	133,276	–	–	﹤0.01%	3483
2023 Q4	$656K	Hold	133,276	–	–	﹤0.01%	3580
2023 Q3	$1.27M	Buy	133,276 +7,300	+6%	+$84.3K	﹤0.01%	3464
2023 Q2	$1.63M	Buy	125,976 +40,637	+48%	+$492K	﹤0.01%	3472
2023 Q1	$1.08M	Buy	+85,339	New	+$1.43M	﹤0.01%	3515

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's ACRV Position: Q1 2026 in Review

State Street held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 67,145 shares worth $93.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

State Street first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.63M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

State Street held 67,145 shares of Acrivon Therapeutics worth $93.3K as of Q1 2026.
State Street left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4040 holding.
State Street first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
State Street's Acrivon Therapeutics position peaked at $1.63M in Q2 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.